Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

388
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
388
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

443
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
443
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

424
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
424
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

420
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
420

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and genetic characterization of genital and inverse psoriasis as a distinct psoriasis endotype.

The Journal of investigative dermatology·2026
Same author

Immunological differences in atopic dermatitis across age groups: insights from single-cell multi-omics.

Journal of translational medicine·2026
Same author

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

The Journal of dermatology·2026
Same author

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.

Dermatology and therapy·2026
Same author

GRAPPA 2025 Annual Meeting: Advances in Psoriatic Disease Research From Pilot Grant Awardees.

The Journal of rheumatology·2026
Same author

Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium.

American journal of clinical dermatology·2026

Related Experiment Video

Updated: Jan 5, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.4K

Anti IL-17 in psoriasis.

Karen Ly1, Mary P Smith1, Quinn Thibodeaux1

  • 1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.

Expert Review of Clinical Immunology
|October 12, 2019
PubMed
Summary

Targeting the interleukin-17A pathway with new biologic therapies offers an effective treatment for moderate-to-severe plaque psoriasis. These IL-17 inhibitors demonstrate a favorable safety profile and rapid, sustained symptom relief.

Keywords:
BiologicsIL-17brodalumabinterleukin-17 inhibitorsixekizumabpsoriasissecukinumab

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K
Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
10:31

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

15.1K

Related Experiment Videos

Last Updated: Jan 5, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.4K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K
Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
10:31

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

15.1K

Area of Science:

  • Immunodermatology
  • Inflammatory diseases
  • Biologic therapies

Background:

  • Psoriasis is a chronic immune-mediated disease with multifactorial pathogenesis.
  • The interleukin-23/T helper 17 (IL-23/Th17) pathway is critical in psoriasis development.
  • Overexpression of IL-17A drives epidermal hyperplasia and inflammation characteristic of psoriasis.

Purpose of the Study:

  • To review the efficacy and safety of approved anti-IL-17 therapies for moderate-to-severe plaque psoriasis.
  • To highlight the role of IL-17 inhibitors in managing psoriasis.
  • To discuss the clinical trial data supporting these treatments.

Main Methods:

  • A literature search was conducted using PubMed.
  • Key phase III clinical trial data for secukinumab, ixekizumab, and brodalumab were reviewed.
  • Efficacy and safety data of IL-17 inhibitors were analyzed.

Main Results:

  • Secukinumab, ixekizumab, and brodalumab are effective IL-17 inhibitors for plaque psoriasis.
  • These therapies show a favorable safety profile in clinical trials.
  • IL-17 antagonists provide rapid onset of action and long-term treatment response.

Conclusions:

  • IL-17 antagonists are effective treatments for moderate-to-severe plaque psoriasis.
  • Targeting the IL-23/Th17 pathway is crucial for managing psoriasis.
  • These biologics offer a significant advancement in psoriasis treatment.